Application of injectable bioactive hydrogel in treatment of recurrent abortion

The injectable bioactive hydrogel prepared by cross-linking aldehyde-modified hyaluronic acid and chitosan, loaded with bioactive factors, solves the problem of recurrent miscarriage caused by endometrial insufficiency, achieves structural and functional restoration of the endometrium, enhances angiogenesis and immune regulation, and supports embryo implantation.

CN120661437APending Publication Date: 2025-09-19AFFILIATED HOSPITAL OF NANTONG UNIV
5 Cites 0 Cited by

Patent Information

Application Number
CN202510899411.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-07-01
Publication Date
2025-09-19

AI Technical Summary

Technical Problem

Existing technologies lack effective biomaterials for restoring the structure and function of the endometrium, especially in recurrent miscarriage, and are unable to effectively address the complex interactions between endometrial receptivity, vascular remodeling, and immune regulation.

Method used

An injectable bioactive hydrogel was prepared by cross-linking aldehyde-modified hyaluronic acid with chitosan, and loaded with leukemia inhibitory factor, vascular endothelial growth factor, interleukin-11 and valproic acid. Rapid gelation was achieved through Schiff base reaction to form a multifunctional delivery carrier.

Benefits of technology

It significantly enhances the proliferation and angiogenesis capacity of endometrial stromal cells, regulates immune response, promotes endometrial regeneration, supports embryo implantation and pregnancy maintenance, and provides potential for local treatment.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides application of injectable bioactive hydrogel in treatment of recurrent abortion, and relates to the technical field of biomedicine, and the technical key points are as follows: aldehydic hyaluronic acid and chitosan are connected in parallel, the injectable bioactive hydrogel is developed, and the hydrogel is loaded with LIF, VEGF, IL-11 and valproic acid to enhance regeneration activity. According to the application, the effect is evaluated in vitro through a specific verification experiment. Results show that the hydrogel prepared by the application shows rapid gelation, good biocompatibility and factor loading capacity, and enhances the proliferation of human endometrial stromal cells and the vascularization capacity of human umbilical vein endothelial cells. In macrophages, the expression of a proinflammatory cytokine is down-regulated, and the expression of an anti-inflammatory cytokine IL-10 is up-regulated. In conclusion, the HA-CHO / chitosan hydrogel in the application supports endometrial regeneration by synergistically promoting proliferation, angiogenesis, immune regulation and receptivity.
Need to check novelty before this filing date? Find Prior Art